Meeting
2016 ASCO Annual Meeting
Towards a safer CD19 CART therapy with reduced risk of cytokine release syndrome (CRS).
Authors
Lucas H. Horan
Eureka Therapeutics, Emeryville, CA
Lucas H. Horan , Cheng Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Cellular Immunotherapy
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3049)
DOI
10.1200/JCO.2016.34.15_suppl.3049
Abstract #
3049
Poster Bd #
371
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.
First Author: Jesus G. Berdeja
Poster
2023 ASCO Annual Meeting
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
First Author: Xinfeng Chen
Poster
2023 ASCO Annual Meeting
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
First Author: Ross Firestone
Poster
2022 ASCO Annual Meeting
Decreasing HPK1 expression in CD19 CAR-T cells: A novel strategy to overcome challenges of cell therapy for adult (r/r) B-ALL.
First Author: Na Zhang